Compare WDFC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | RLAY |
|---|---|---|
| Founded | 1953 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 1995 | 2020 |
| Metric | WDFC | RLAY |
|---|---|---|
| Price | $219.23 | $13.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $270.00 | $17.44 |
| AVG Volume (30 Days) | 186.9K | ★ 3.2M |
| Earning Date | 04-09-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | 30.92 | ★ 31.78 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $488,109,000.00 | $15,355,000.00 |
| Revenue This Year | $8.23 | N/A |
| Revenue Next Year | $5.85 | $324.03 |
| P/E Ratio | $79.68 | ★ N/A |
| Revenue Growth | 19.49 | ★ 53.44 |
| 52 Week Low | $175.38 | $2.71 |
| 52 Week High | $253.24 | $17.32 |
| Indicator | WDFC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 45.07 |
| Support Level | $212.30 | $6.67 |
| Resistance Level | $225.39 | $17.32 |
| Average True Range (ATR) | 7.54 | 1.08 |
| MACD | 1.91 | -0.33 |
| Stochastic Oscillator | 69.19 | 2.99 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.